NuCana Stock Forecast, Price & News

-0.18 (-5.66 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.77 million shs
Average Volume995,799 shs
Market Capitalization$145.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NuCana logo

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.37 out of 5 stars

Medical Sector

774th out of 2,099 stocks

Pharmaceutical Preparations Industry

383rd out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NuCana (NASDAQ:NCNA) Frequently Asked Questions

Is NuCana a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NuCana stock.
View analyst ratings for NuCana
or view top-rated stocks.

What stocks does MarketBeat like better than NuCana?

Wall Street analysts have given NuCana a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NuCana wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NuCana?

NuCana saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 329,200 shares, an increase of 39.3% from the April 29th total of 236,300 shares. Based on an average daily volume of 226,400 shares, the days-to-cover ratio is currently 1.5 days.
View NuCana's Short Interest

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Wednesday, August 18th 2021.
View our earnings forecast for NuCana

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) released its quarterly earnings data on Tuesday, May, 18th. The company reported ($19.00) earnings per share for the quarter, missing the Zacks' consensus estimate of ($16.86) by $2.14.
View NuCana's earnings history

How has NuCana's stock price been impacted by COVID-19 (Coronavirus)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NCNA shares have decreased by 52.7% and is now trading at $3.00.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NCNA?

6 analysts have issued 1-year price objectives for NuCana's stock. Their forecasts range from $10.00 to $22.00. On average, they anticipate NuCana's stock price to reach $17.50 in the next year. This suggests a possible upside of 483.3% from the stock's current price.
View analysts' price targets for NuCana
or view top-rated stocks among Wall Street analysts.

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Mr. Hugh Stephen Griffith, Founder, CEO & Exec. Director (Age 53, Pay $1.3M)
  • Mr. Donald Munoz, Chief Financial Officer (Age 52)
  • Prof. Christopher B. Wood, Chief Medical Officer (Age 75, Pay $117.41k)
  • Mr. David Harrison, Head of Translational Medicine
  • Ms. Theresa Bruce, Sr. VP of Clinical Operations
  • Ms. Elisabeth Oelmann, Sr. VP of Medical & Clinical Devel.
  • Martin Quinn, Company Sec.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

Who are NuCana's major shareholders?

NuCana's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.55%), Sectoral Asset Management Inc (2.30%), Harvard Management Co. Inc. (2.05%), Granite Point Capital Management L.P. (1.38%), Renaissance Technologies LLC (0.94%) and Alps Advisors Inc. (0.19%).

Which major investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Millennium Management LLC, and Blair William & Co. IL.

Which major investors are buying NuCana stock?

NCNA stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Baillie Gifford & Co., Henry James International Management Inc., Hilltop Holdings Inc., Alps Advisors Inc., Renaissance Technologies LLC, Granite Point Capital Management L.P., and HRT Financial LP.

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $3.00.

How much money does NuCana make?

NuCana has a market capitalization of $145.47 million. The company earns $-39,400,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does NuCana have?

NuCana employs 27 workers across the globe.

What is NuCana's official website?

The official website for NuCana is

Where are NuCana's headquarters?

NuCana is headquartered at 3 Lochside Way, Edinburgh X0, EH12 9DT.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.